DEVELOP AND DELIVER
Staying true to our vision to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics, SOFIE has acquired global rights for the diagnostic and companion diagnostic use of the FAPI family of compounds from University of Heidelberg, the team that invented PSMA-617 (Novartis). The FAPI family of compounds have demonstrated promising theranostic potential.
Fibroblast activation protein (FAP) is a well-known target shown to be overexpressed on cancer associated fibroblasts (CAFs) present in the tumor microenvironment across a variety of cancer types. In addition to oncology, FAP overexpression has been linked to non-malignant processes and disease, including wound healing, chronic inflammation, myocardial infarction, benign tumors and fibrosis. The FAP inhibitor family of compounds (FAPI) allows non-invasive visualization of this important target for oncology and non-oncology indications through binding to FAP with low nanomolar affinity. These compounds can be labeled with various isotopes, including Gallium-68 and Florine-18, for use in PET imaging.